Glide Technologies recently announced a subcontract extension for the advancement of an alternative delivery method for Pfenex’s recombinant Protective Antigen, Px563L-mrPA, utilising the Glide Technologies solid dose formulation technology. This contract continuation is the result of the National Institute of Allergy and Infectious Diseases (NIAID) exercising its first contract option under its existing contract (HHSN272201200033C) with Pfenex. “We are pleased with the early results and the development of this potential additional path for our anthrax vaccine program.” stated Bertrand C. Liang, Chief Executive Officer of Pfenex. “We appreciate the additional funding support provided by NIAID for this program and look forward to continuing this successful collaboration.” “Following encouraging stability data with initial formulations we are pleased that NIAID continues to fund the progression of this program. We believe that a combination of Pfenex’s proprietary rPA-based anthrax vaccine and Glide’s novel formulations and delivery technology will address key issues with current products designed for a response to an anthrax bio-threat.” stated Dr Mark Carnegie-Brown, Chief Executive Officer of Glide Technologies.
Pfenex Exercises Glide Contract Extension for Solid Dose Formulation of Recombinant Protective Antigen
Subscribe to the DPJ Weekly Brief newsletter: Subscribe